healthcare policy
Invited Paper
Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Larry D. Lynd, Eric Lun, Bob Nakagawa, Dean Regier, Shi...
Commentary
Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
Kristina Jenei and Bishal Gyawali
Commentary
Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
Melanie McPhail and Tania Bubela
The Authors Respond
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Eric Lun, Bob Nakagawa, Dean Regier, Shirin Rizzardo an...
Research Paper
Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective
Reed F. Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R. Houston, Aaron S. Kessel...
Commentary
Virtual Care in Canada as of the Sixth Wave of the COVID-19 Pandemic: Finding the Right Balance – An Indigenous Perspective
Michael A.B. Anderson
The Author Responds
Response to Commentaries on Virtual Care as of the Sixth Wave of the COVID-19 Pandemic
William Falk